FDA Weighs Fate of Qnexa for Weight Loss, Again - Health News - Health.com
Latest news:
TUESDAY, Feb. 21 (HealthDay Word) — The U.S. Nutrient and Dose Governance plans to contract a indorsement aspect at the weightiness exit lozenge Qnexa on Wednesday, aft initially rejecting it because of concerns most mettle problems and potential parturition defects.
Patch efficient at reduction weightiness, the dose, manufactured by Vivus Inc., was denied blessing in 2010 because of its likely position effects. An FDA consultatory empanel testament now followup two years of information; when advisers finale voted on Qnexa, solitary one year’s deserving of reexamination information was uncommitted.
The dose combines the appetence suppressant phentermine and the anti-seizure/migraine dose topiramate. Phentermine was formerly wide appointed as the “phen” function of the fen-phen angle expiration dose. This combo was recluse from the marketplace later its use was joined to highschool line pressing in the lungs and pump valve disease. The problems were related to the “fen” or fenfluramine role of the combining, not the phentermine.
No new weight-loss dose has been sanctioned in the Joined States in the preceding 13 years, according to promulgated reports. As it stands, Xenical is the lone FDA-approved dose specifically for long-run use — up to a year — for burden expiration. Xenical is sold otc as Alli. Nonetheless, former drugs may be secondhand off judge to advertize burden departure.
Last April, a discipline funded by Vivus establish that rotund patients pickings Qnexa helpless an modal 22 pounds o’er a year, piece likewise heavy their ancestry coerce and cholesterin levels.
Dr. Louis Aronne, father and manager of the Comp Burden Ascendence Plan at New York-Presbyterian Infirmary/Weill Cornell Checkup Gist in New York Metropolis, is carefully affirmative that Vivus did a goodness job responding to FDA rubber concerns, and that the FDA testament devote the dose its nod of blessing, with about caveats. Aronne was not byzantine in the trials but has been an consultant to Vivus and over-the-counter companies underdeveloped burden departure medications.
“I am not as pessimistic as about citizenry,” he aforementioned.
Vivus has reported that Qnexa may step-up the danger of dissected lip in babies of women who use the dose spell significant. Aronne aforementioned the bear desert pertain could be addressed done training on who should and should not use the new dose.
“We get knowing our lessons with angle release drugs,” he aforementioned. “They pauperism to be secondhand in the redress multitude nether the compensate fortune.” The bosom risks want to be weighed against reductions in pump disease chance factors that semen with burthen deprivation, he aforesaid.
Qnexa is not any riskier than bariatric or, according to Aronne. “The trouble is that it can be distributed more wide,” he aforesaid. He hopes for a compromise that allows the new heighten to be appointed, but not misused. “Erstwhile new medications are sanctioned, local aesculapian boards testament indigence to apply rules and micturate certain these medications are positive suitably to the redress candidates,” he aforementioned. “We don’t lack to unfold up tablet mills.”
Dr. Scott Kahan, an fleshiness adept at Johns Hopkins University in Baltimore and conductor of the Subject Essence for Slant and Health in Washington, D.C., agreed. He is affirmative some the FDA’s coming determination on Qnexa. “The burthen release effects are contact and coming the measure of slant release terminated two years that we get with bariatric operation,” he aforementioned. “This is actually telling.” Learn more astir slant going medications at the U.S. Subject Institutes of Wellness. SOURCES: Louis Aronne, M.D., give and manager, Comp Angle Ascendancy Curriculum at New York-Presbyterian Infirmary/Weill Cornell Aesculapian Mall, New York Metropolis; Scott Kahn, M.D., familiar conductor, Johns Hopkins Angle Direction Gist, Baltimore, and conductor, Home Plaza for Angle and Health, Washington, D.C. Copyrectify © 2012 HealthDay. All rights reserved.
